1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Correction: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024

MARKN.

This is a correction of the press release published on 27 March 2025 at 08:30 CET, titled “Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024”

In the previously published press release, it was incorrectly stated that the attached year-end report for 2024 had been reviewed by the company’s auditors. This is not correct – the report had not been subject to auditor review at the time of publication.
 
The correct version of the Q4 report is attached to this press release.

Contacts Justin & Aaron

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

Correction: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024
Interim Report Q4 2024

Datum 2025-04-25, kl 16:30
Källa MFN
Bifogade filer
Correction: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024
Interim Report Q4 2024